Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
ORILISSA (elagolix) tablets for oral administration contain elagolix sodium, the sodium salt of the active moiety elagolix. Elagolix sodium is a nonpeptide small molecule, GnRH receptor antagonist. Elagolix sodium is chemically described as sodium 4-({(1R)-2-[5-(2-fluoro-3methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino)butanoate. Elagolix sodium has a molecular formula of C32H29F5N3O5Na and a molecular weight of 653.58. Elagolix free acid has a molecular weight of 631.60.
Elagolix sodium has the following structural formula:
 |
Elagolix sodium is a white to off white to light yellow powder and is freely soluble in water.
ORILISSA 150 mg tablets are light pink, oblong, film-coated tablets with “EL 150” debossed on one side. Each tablet contains 155.2 mg of elagolix sodium (equivalent to 150 mg of elagolix) as the active ingredient and the following inactive ingredients: mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and carmine high tint.
ORILISSA 200 mg tablets are light orange, oblong, film-coated tablets with “EL 200” debossed on one side. Each tablet contains 207.0 mg of elagolix sodium (equivalent to 200 mg of elagolix) as the active ingredient and the following inactive ingredients: mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide red.
ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis.
Limit the duration of use based on the dose and coexisting condition (see Table 1) [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
Table 1. Recommended Dosage and Duration of Use
| Dosing Regimen | Maximum Treatment Duration | Coexisting Condition |
| Initiate treatment with ORILISSA 150 mg once daily | 24 months | None |
| Consider initiating treatment with ORILISSA 200 mg twice daily | 6 months | Dyspareunia |
| Initiate treatment with ORILISSA 150 mg once daily. Use of 200 mg twice daily is not recommended. | 6 months | Moderate hepatic impairment (Child-Pugh Class B) |
No dosage adjustment of ORILISSA is required in women with mild hepatic impairment (Child-Pugh A).
Compared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures. Because of these increased exposures and risk for bone loss:
Instruct the patient to take a missed dose of ORILISSA on the same day as soon as she remembers and then resume the regular dosing schedule.
The 150 mg tablets are light pink, oblong, film-coated tablets with “EL 150” debossed on one side. Each tablet contains 155.2 mg of elagolix sodium equivalent to 150 mg of elagolix.
The 200 mg tablets are light orange, oblong, film-coated tablets with “EL 200” debossed on one side. Each tablet contains 207.0 mg of elagolix sodium equivalent to 200 mg of elagolix.
ORILISSA tablets are available in two strengths: 150 mg and 200 mg, which are equivalent to 155.2 mg and 207.0 mg of elagolix sodium, respectively.
ORILISSA 150 mg tablets are light pink, oblong, film-coated tablets with “EL 150” debossed on one side. ORILISSA 150 mg tablets are packaged in weekly blister packs. Each blister pack contains 7 tablets supplying the drug product for one week. Four blister packs (a total of 28 tablets) are packaged into a carton that provides the drug product for 4 weeks (NDC 0074-003828).
ORILISSA 200 mg tablets are light orange, oblong, film-coated tablets with “EL 200” debossed on one side. The 200 mg tablets are packaged in weekly blister packs. Each blister pack contains 14 tablets supplying the drug product for one week. Four blister packs (a total of 56 tablets) are packaged in a carton that provides the drug product for 4 weeks (NDC 0074-0039-56).
Store at 2°C to 30°C (36°F to 86°F).
Dispose unused medication via a take-back option if available. Otherwise, follow FDA instructions for disposing medication in the household trash, www.fda.gov/drugdisposal. Do NOT flush down the toilet.
Manufactured by AbbVie Inc. North Chicago, IL 60064. Revised: Jun 2023.
The following serious adverse reactions are discussed elsewhere in labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of ORILISSA was evaluated in two six-month, randomized, double-blind, placebo-controlled clinical trials [EM-1 (NCT01620528) and EM-2 (NCT01931670)] in which a total of 952 adult women with moderate to severe pain associated with endometriosis were treated with ORILISSA (475 with 150 mg once daily and 477 with 200 mg twice daily) and 734 were treated with placebo. The population age range was 18-49 years old. Women who completed six months of treatment and met eligibility criteria continued treatment in two uncontrolled, blinded six-month extension trials [EM-3 (NCT01760954) and EM-4 (NCT02143713)], for a total treatment duration of up to 12 months.
Overall, the most common serious adverse events reported for subjects treated with ORILISSA in the two placebo-controlled clinical trials (Studies EM-1 and EM-2) included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%). In these trials, 0.2% of subjects treated with ORILISSA 150 mg once daily and 0.2% of subjects treated with ORILISSA 200 mg twice daily discontinued therapy due to serious adverse reactions compared to 0.5% of those given placebo.
In the two placebo-controlled clinical trials (Studies EM-1 and EM-2), 5.5% of subjects treated with ORILISSA 150 mg once daily and 9.6% of subjects treated with ORILISSA 200 mg twice daily discontinued therapy due to adverse reactions compared to 6.0% of those given placebo. Discontinuations were most commonly due to hot flushes or night sweats (1.1% with 150 mg once daily and 2.5% with 200 mg twice daily) and nausea (0.8% with 150 mg once daily and 1.5% with 200 mg twice daily) and were dose-related. The majority of discontinuations due to hot flushes or night sweats (10 of 17, 59%) and nausea (7 of 11, 64%) occurred within the first 2 months of therapy.
In the two extension trials (Studies EM-3 and EM-4), discontinuations were most commonly due to decreased BMD and were dose-related. In these trials, 0.3% of subjects treated with ORILISSA 150 mg once daily and 3.6% of subjects treated with ORILISSA 200 mg twice daily discontinued therapy due to decreased BMD.
Adverse reactions reported in ≥ 5% of women in the two placebo-controlled trials in either ORILISSA dose group and at a greater frequency than placebo are noted in the following table.
Table 2. Percentage of Subjects in Studies EM-1 and EM-2 with Treatment-Emergent Adverse Reactions Occurring in at Least 5% of Subjects (either ORILISSA Dose Group) and at a Greater Incidence than with Placebo
| ORILISSA 150 mg Once Daily N=475 |
ORILISSA 200 mg Twice Daily N=477 |
Placebo N=734 |
|
| % | % | % | |
| Hot Flush | 24 | 46 | 9 |
| Headache | 17 | 20 | 12 |
| Nausea | 11 | 16 | 13 |
| Insomnia | 6 | 9 | 3 |
| Mood altered, mood swings | 6 | 5 | 3 |
| Amenorrhea | 4 | 7 | <1 |
| Depressed mood, depression, depressive symptoms and/or tearfulness | 3 | 6 | 2 |
| Anxiety | 3 | 5 | 3 |
| Arthralgia | 3 | 5 | 3 |
The most commonly reported adverse reactions in the extension trials (EM-3 and EM-4) were similar to those in the placebo-controlled trials.
In Study EM-1 and Study EM-2, adverse reactions reported in ≥ 3% and < 5% in either ORILISSA dose group and greater than placebo included: decreased libido, diarrhea, abdominal pain, weight gain, dizziness, constipation and irritability.
The effect of ORILISSA on BMD was assessed by dual-energy X-ray absorptiometry (DXA).
In Studies EM-1 and EM-2, there was a dose-dependent decrease in BMD in ORILISSA-treated subjects compared to an increase in placebo-treated subjects.
In Study EM-1, compared to placebo, the mean change from baseline in lumbar spine BMD at 6 months was -0.9% (95% CI: -1.3, -0.4) with ORILISSA 150 mg once daily and -3.1% (95% CI: 3.6, -2.6) with ORILISSA 200 mg twice daily (Table 3). The percentage of subjects with greater than 8% BMD decrease in lumbar spine, total hip or femoral neck at any time point during the placebo-controlled treatment period was 2% with ORILISSA 150 mg once daily, 7% with ORILISSA 200 mg twice daily and < 1% with placebo. In the blinded extension Study EM-3, continued bone loss was observed with 12 months of continuous treatment with ORILISSA. The percentage of subjects with greater than 8% BMD decrease in lumbar spine, total hip or femoral neck at any time point during the extension treatment period was 8% with continuous ORILISSA 150 mg once daily and 21% with continuous ORILISSA 200 mg twice daily.
In Study EM-2, compared to placebo, the mean change from baseline in lumbar spine BMD at 6 months was -1.3% (95% CI: -1.8, -0.8) with ORILISSA 150 mg once daily and -3.0% (95% CI: 3.5, -2.6) with ORILISSA 200 mg twice daily (Table 3). The percentage of subjects with greater than 8% BMD decrease in lumbar spine, total hip or femoral neck at any time point during the placebo-controlled treatment period was < 1% with ORILISSA 150 mg once daily, 6% with ORILISSA 200 mg twice daily and 0% with placebo. In the blinded extension Study EM-4, continued bone loss was observed with 12 months of continuous treatment with ORILISSA. The percentage of subjects with greater than 8% BMD decrease in lumbar spine, total hip or femoral neck at any time point during the extension treatment period was 2% with continuous ORILISSA 150 mg once daily and 21% with continuous ORILISSA 200 mg twice daily.
Table 3. Percent Change from Baseline in Lumbar Spine BMD at Month 6
| ORILISSA 150 mg Once Daily |
ORILISSA 200 mg Twice Daily |
Placebo | |
| EM-1 | |||
| N | 183 | 180 | 277 |
| Percent Change from Baseline, % | -0.3 | -2.6 | 0.5 |
| Treatment Difference, % (95% CI) | -0.9 (-1.3, -0.4) |
-3.1 (-3.6, -2.6) |
|
| EM-2 | |||
| N | 174 | 183 | 271 |
| Percent Change from Baseline, % | -0.7 | -2.5 | 0.6 |
| Treatment Difference, % (95% CI) | -1.3 (-1.8, -0.8) |
-3.0 (-3.5, -2.6) |
|
To assess for recovery, the change in lumbar spine BMD over time was analyzed for subjects who received continuous treatment with ORILISSA 150 mg once daily or ORILISSA 200 mg twice daily for up to 12 months and who were then followed after cessation of therapy for an additional 6 months. Partial recovery of BMD was seen in these subjects (Figure 1).
In Study EM-3, if a subject had BMD loss of more than 1.5% at the lumbar spine or more than 2.5% at the total hip at the end of treatment, follow-up DXA was required after 6 months off-treatment. In Study EM-4, all subjects were required to have a follow-up DXA 6 months off treatment regardless of change in BMD and if a subject had BMD loss of more than 1.5% at the lumbar spine or more than 2.5% at the total hip after 6 months off treatment, follow-up DXA was required after 12 months off-treatment. Figure 2 shows the change in lumbar spine BMD for the subjects in Study EM-2/EM-4 who completed 12 months of treatment with ORILISSA and who had a follow-up DXA 12-months off treatment.
Figure 1. Percent Change from Baseline in Lumbar Spine BMD in Subjects Who Received 12 Months of ORILISSA and Had Follow-up BMD 6 Months off Therapy in Studies EM2/EM-4
 |
Figure 2. Percent Change from Baseline in Lumbar Spine BMD in Subjects Who Received 12 Months of ORILISSA and Had Follow-up BMD 12 Months off Therapy in Studies EM2/EM-4
 |
In the placebo-controlled trials (Studies EM-1 and EM-2), ORILISSA was associated with adverse mood changes (see Table 2 and Table 4), particularly in those with a history of depression.
Table 4. Suicidal Ideation and Suicidal Behavior in Studies EM-1 and EM-2
| Adverse Reactions | ORILISSA | Placebo (N=734) n (%) |
|
| 150 mg Once Daily (N=475) n (%) |
200 mg Twice Daily (N=477) n (%) |
||
| Completed suicide | 1 (0.2) | 0 | 0 |
| Suicidal ideation | 1 (0.2) | 1 (0.2) | 0 |
A 44-year-old woman received 31 days of ORILISSA 150 mg once daily then completed suicide 2 days after ORILISSA discontinuation. She had no relevant past medical history; life stressors were noted.
Among the 2090 subjects exposed to ORILISSA in the endometriosis Phase 2 and Phase 3 studies, there were four reports of suicidal ideation. In addition to the two subjects in Table 4, there were two additional reports of suicidal ideation: one subject in EM-3 (150 mg once daily) and one in a Phase 2 study (75 mg once daily, an unapproved dose). Three of these subjects had a history of depression. Two subjects discontinued ORILISSA and two completed the clinical trial treatment periods.
In the placebo-controlled clinical trials (Studies EM-1 and EM-2), dose-dependent asymptomatic elevations of serum ALT to at least 3-times the upper limit of the reference range occurred during treatment with ORILISSA (150 mg once daily – 1/450, 0.2%; 200 mg twice daily – 5/443, 1.1%; placebo – 1/696, 0.1%). Similar increases were seen in the extension trials (Studies EM-3 and EM-4).
Dose-dependent increases in total cholesterol, low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and serum triglycerides were noted during ORILISSA treatment in EM-1 and EM-2. In EM-1 and EM-2, 12% and 1% of subjects with mildly elevated LDL-C (130-159 mg/dL) at baseline had an increase in LDL-C concentrations to 190 mg/dL or higher during treatment with ORILISSA and placebo, respectively. In EM-1 and EM-2, 4% and 1% of subjects with mildly elevated serum triglycerides (150-300 mg/dL) at baseline had an increase in serum triglycerides to at least 500 mg/dL during treatment with ORILISSA and placebo, respectively. The highest measured serum triglyceride concentration during treatment with ORILISSA was 982 mg/dL.
Table 5. Mean Change and Maximum Increase from Baseline in Serum Lipids in Studies EM-1 and EM-2
| ORILISSA 150 mg Once Daily N=475 |
ORILISSA 200 mg Twice Daily N=477 |
Placebo N=734 |
|
| LDL-C (mg/dL) | |||
| Mean change at Month 6 | 5 | 13 | -3 |
| Maximum increase during Treatment Period | 137 | 107 | 122 |
| HDL-C (mg/dL) | |||
| Mean change at Month 6 | 2 | 4 | 1 |
| Maximum increase during Treatment Period | 43 | 52 | 45 |
| Triglycerides (mg/dL) | |||
| Mean change at Month 6 | <1 | 11 | -3 |
| Maximum increase during Treatment Period | 624 | 484 | 440 |
Lipid increases occurred within 1 to 2 months after the start of ORILISSA and remained stable thereafter over 12 months.
In Studies EM-1 and EM-2, non-serious hypersensitivity reactions including rash occurred in 5.8% of ORILISSA treated-subjects and 6.1% of placebo-treated subjects. These events led to study drug discontinuation in 0.4% of ORILISSA-treated subjects and 0.5% of placebo-treated subjects.
The effects of ORILISSA on menstrual bleeding were evaluated for up to 12 months using an electronic daily diary where subjects classified their flow of menstrual bleeding (if present in the last 24 hours) as spotting, light, medium, or heavy. ORILISSA led to a dose-dependent reduction in mean number of bleeding and spotting days and bleeding intensity in those subjects who reported menstrual bleeding.
Table 6. Mean Bleeding/Spotting Days and Mean Intensity Scores at Month 3
| ORILISSA 150mg Once Daily |
ORILISSA 200mg Twice Daily |
Placebo | ||||
| Baseline | Month 3 | Baseline | Month 3 | Baseline | Month 3 | |
| Mean bleeding/ spotting days in prior 28 days | 5.3 | 2.8 | 5.7 | 0.8 | 5.4 | 4.6 |
| Mean Intensity scorea | 2.6 | 2.2 | 2.5 | 2.0 | 2.6 | 2.4 |
| aIntensity for subjects who reported at least 1 day of bleeding or spotting during 28 day interval. Scale ranges from 1 to 4, 1 = spotting, 2 = light, 3 = medium, 4 = heavy |
||||||
ORILISSA also demonstrated a dose-dependent increase in the percentage of women with amenorrhea (defined as no bleeding or spotting in a 56-day interval) over the treatment period. The incidence of amenorrhea during the first six months of treatment ranged from 6-17% for ORILISSA 150 mg once daily, 13-52% for ORILISSA 200 mg twice daily and less than 1% for placebo. During the second 6 months of treatment, the incidence of amenorrhea ranged from 1115% for ORILISSA 150 mg once daily and 46-57% for ORILISSA 200 mg twice daily.
After 6 months of therapy with ORILISSA 150 mg once daily, resumption of menses after stopping treatment was reported by 59%, 87% and 95% of women within 1, 2, and 6 months, respectively. After 6 months of therapy with ORILISSA 200 mg twice daily, resumption of menses after stopping treatment was reported by 60%, 88%, and 97% of women within 1, 2, and 6 months, respectively.
After 12 months of therapy with ORILISSA 150 mg once daily resumption of menses after stopping treatment was reported by 77%, 95% and 98% of women within 1, 2, and 6 months respectively. After 12 months of therapy with ORILISSA 200 mg twice daily resumption of menses after stopping treatment was reported by 55%, 91% and 96% of women within 1, 2, and 6 months respectively.
The following adverse reactions have been identified during post-approval use of ORILISSA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune system disorders: hypersensitivity reactions (including anaphylaxis, angioedema, and urticaria).
Elagolix is:
The effects of co-administration of ORILISSA on concentrations of concomitant drugs and the clinical recommendations for these drug interactions are summarized in Table 7.
Table 7. Drug Interactions: Effects of ORILISSA on Other Drugs
| Concomitant Drug Class: Drug Name |
Effect on Plasma Exposure of Concomitant Drug | Clinical Recommendations |
| Cardiac glycosides: digoxin |
↑ digoxin | Increase monitoring of digoxin concentrations and potential signs and symptoms of clinical toxicity when initiating ORILISSA in patients who are taking digoxin. If ORILISSA is discontinued, increase monitoring of digoxin concentrations. |
| Benzodiazepines: oral midazolam |
↓ midazolam | Consider increasing the dose of midazolam by no more than 2-fold and individualize midazolam therapy based on the patient’s response. |
| Statins: rosuvastatin |
↓ rosuvastatin | Monitor lipid levels and adjust the dose of rosuvastatin, if necessary. |
| Proton pump inhibitors: omeprazole |
↑ omeprazole | No dose adjustment needed for omeprazole 40 mg once daily when co-administered with ORILISSA. When ORILISSA is used concomitantly with higher doses of omeprazole, consider dosage reduction of omeprazole. |
| Combined hormonal contraceptives: oral ethinyl estradiol/levonorgestrel |
↑ethinyl estradiol ↓levonorgestrel | Advise women to use effective non-hormonal contraception during treatment with ORILISSA and for 28 days after discontinuing ORILISSA. |
| See Tables 10 and 11 [see CLINICAL PHARMACOLOGY]. The direction of the arrow indicates the direction of the change in the area under the curve (AUC) (↑= increase, ↓ = decrease). |
||
Elagolix is a substrate of CYP3A, P-gp, and OATP1B1.
Concomitant use of ORILISSA 200 mg twice daily and strong CYP3A inhibitors for more than 1 month is not recommended. Limit concomitant use of ORILISSA 150 mg once daily and strong CYP3A inhibitors to 6 months. Co-administration of ORILISSA with strong CYP3A inducers may decrease elagolix plasma concentrations and may result in a decrease of the therapeutic effects of ORILISSA.
Concomitant use of ORILISSA 200 mg twice daily and rifampin is not recommended. Limit concomitant use of ORILISSA 150 mg once daily and rifampin to 6 months.
The effect of concomitant use of P-gp inhibitors or inducers on the pharmacokinetics of ORILISSA is unknown. OATP1B1 inhibitors that are known or expected to significantly increase elagolix plasma concentrations are contraindicated due to increased risk of elagolixassociated adverse reactions [see CONTRAINDICATIONS].
Included as part of the "PRECAUTIONS" Section
ORILISSA causes a dose-dependent decrease in bone mineral density (BMD). BMD loss is greater with increasing duration of use and may not be completely reversible after stopping treatment [see ADVERSE REACTIONS]. The impact of these BMD decreases on long-term bone health and future fracture risk are unknown.
ORILISSA is contraindicated in women with known osteoporosis [see CONTRAINDICATIONS]. Consider assessment of BMD in patients with a history of a low-trauma fracture or other risk factors for osteoporosis or bone loss. Limit the duration of use to reduce the extent of bone loss [see DOSAGE AND ADMINISTRATION]. Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients.
Women who take ORILISSA may experience a reduction in the amount, intensity or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of a pregnancy in a timely manner [see ADVERSE REACTIONS]. Perform pregnancy testing if pregnancy is suspected, and discontinue ORILISSA if pregnancy is confirmed.
Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with ORILISSA in the endometriosis clinical trials. ORILISSA subjects had a higher incidence of depression and mood changes compared to placebo, and ORILISSA subjects with a history of suicidality or depression had a higher incidence of depression compared to subjects without such a history [see ADVERSE REACTIONS]. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits [see ADVERSE REACTIONS]. Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional, as appropriate. Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing ORILISSA if such events occur.
In clinical trials, dose-dependent elevations of serum alanine aminotransferase (ALT) at least 3times the upper limit of the reference range occurred with ORILISSA. Use the lowest effective dose of ORILISSA and instruct patients to promptly seek medical attention in case of symptoms or signs that may reflect liver injury, such as jaundice. Promptly evaluate patients with elevations in liver tests to determine whether the benefits of continued therapy outweigh the risks [see ADVERSE REACTIONS].
Advise women to use effective non-hormonal contraceptives during treatment with ORILISSA and for 28 days after discontinuing ORILISSA [see Use In Specific Populations, DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
Co-administration of a combined oral contraceptive (COC) (containing 20 mcg ethinyl estradiol/0.1 mg levonorgestrel) following administration of ORILISSA 200 mg twice daily for 14 days increases the plasma ethinyl estradiol concentration by 2.2-fold compared to this COC alone. ORILISSA 200 mg twice daily co-administered with a COC containing ethinyl estradiol may lead to increased risk of ethinyl estradiol-related adverse events including thromboembolic disorders and vascular events and is not recommended [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
Co-administration of ORILISSA 200 mg twice daily and a COC containing 0.1 mg levonorgestrel decreases the plasma concentrations of levonorgestrel by 27%, potentially affecting contraceptive efficacy. Co-administration of ORILISSA with COCs containing norethindrone acetate did not show reduction in plasma concentrations of norethindrone [see DRUG INTERACTIONS, CLINICAL PHARMACOLOGY].
Co-administration of ORILISSA with progestin-containing intrauterine contraceptive systems has not been studied.
Based on the mechanism of action of ORILISSA, estrogen-containing contraceptives are expected to reduce the efficacy of ORILISSA. The effect of progestin-only contraceptives on the efficacy of ORILISSA is unknown.
Advise patients to read the FDA-approved patient labeling (Medication Guide).
Inform patients about the risk of bone loss. Advise patients that supplementary calcium and vitamin D may be beneficial if dietary intake of calcium and vitamin D is not adequate [see WARNINGS AND PRECAUTIONS].
Advise women that ORILISSA may delay the recognition of pregnancy because it may reduce the amount, intensity, or duration of menstrual bleeding. Advise patients to use effective non-hormonal contraception while taking ORILISSA and to discontinue ORILISSA if pregnancy is confirmed. Advise pregnant women that there is a pregnancy registry that monitors outcomes in women who become pregnant while treated with ORILISSA. Inform patients they can enroll by calling 1-833-782-7241 or visiting https://www.bloompregnancyregistry.com [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
Advise patients that suicidal ideation and exacerbation of mood disorders may occur with ORILISSA use. Instruct patients to seek immediate medical attention for suicidal ideation and behavior and for new onset or worsening depression, anxiety, or other mood changes [see WARNINGS AND PRECAUTIONS].
Advise patients to promptly seek medical attention in case of signs or symptoms that may reflect liver injury, such as jaundice [see WARNINGS AND PRECAUTIONS].
Instruct a patient who miss a dose of ORILISSA to take the missed dose on the same day as soon as she remembers and then resume the regular dosing schedule:
Instruct patients to dispose of unused medication via a take-back option if available or to otherwise follow FDA instructions for disposing of medication in the household trash, www.fda.gov/drugdisposal, and NOT to flush down the toilet.
Two-year carcinogenicity studies conducted in mice (50, 150, or 500 mg/kg/day) and rats (150, 300, or 800 mg/kg/day) that administered elagolix by the dietary route revealed no increase in tumors in mice at up to 19-fold the MRHD based on AUC. In the rat, there was an increase in thyroid (male and female) and liver (males only) tumors at the high dose (12 to 13-fold the MRHD). The rat tumors were likely species-specific and of negligible relevance to humans.
Elagolix was not genotoxic or mutagenic in a battery of tests, including the in vitro bacterial reverse mutation assay, the in vitro mammalian cell forward mutation assay at the thymidine kinase (TK+/-) locus in L5178Y mouse lymphoma cells, and the in vivo mouse micronucleus assay.
In a fertility study conducted in the rat, there was no effect of elagolix on fertility at any dose (50, 150, or 300 mg/kg/day). Based on AUC, the exposure multiple for the MRHD in women compared to the highest dose of 300 mg/kg/day in female rats is approximately 5-fold. However, because elagolix has low affinity for the GnRH receptor in the rat [see Use In Specific Populations], and because effects on fertility are most likely to be mediated via the GnRH receptor, these data have low relevance to humans.
There is a pregnancy registry that monitors pregnancy outcomes in women exposed to ORILISSA during pregnancy . Healthcare providers are encouraged to register patients, or pregnant women may enroll themselves in the registry by calling 1-833-782-7241 or visiting https://www.bloompregnancyregistry.com.
Use of ORILISSA is contraindicated in pregnant women. Exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss. Discontinue ORILISSA if pregnancy occurs during treatment.
The limited human data with the use of ORILISSA in pregnant women are insufficient to determine whether there is a risk for major birth defects or miscarriage. Although two cases of congenital malformations were reported in clinical trials with ORILISSA, no pattern was identified and miscarriages were reported at a similar incidence across treatment groups (see Data).
When pregnant rats and rabbits were orally dosed with elagolix during the period of organogenesis, postimplantation loss was observed in pregnant rats at doses 20 times the maximum recommended human dose (MRHD). Spontaneous abortion and total litter loss was observed in rabbits at doses 7 and 12 times the MRHD. There were no structural abnormalities in the fetuses at exposures up to 40 and 12 times the MRHD for the rat and rabbit, respectively (see Data).
Human Data
There were 49 pregnancies reported in clinical trials of more than 3,500 women (of whom more than 2,000 had endometriosis) treated with ORILISSA for up to 12 months. These pregnancies occurred while the women were receiving ORILISSA or within 30 days after stopping ORILISSA. Among these 49 pregnancies, two major congenital malformations were reported. In one case of infant cleft palate, the mother was treated with ORILISSA 150 mg daily and the estimated fetal exposure to ORILISSA occurred during the first 30 days of pregnancy. In one case of infant tracheoesophageal fistula, the mother was treated with ORILISSA 150 mg daily and the estimated fetal exposure to ORILISSA occurred during the first 15 days of pregnancy.
Among these 49 pregnancies, there were five cases of spontaneous abortion (miscarriage) compared to five cases among the 20 pregnancies that occurred in more than 1100 women treated with placebo. Although the duration of fetal exposure was limited in ORILISSA clinical trials, there were no apparent decreases in birth weights associated with ORILISSA in comparison to placebo.
Animal Data
Embryofetal development studies were conducted in the rat and rabbit. Elagolix was administered by oral gavage to pregnant rats (25 animals/dose) at doses of 0, 300, 600 and 1200 mg/kg/day and to rabbits (20 animals/dose) at doses of 0, 100, 150, and 200 mg/kg/day, during the period of organogenesis (gestation day 6-17 in the rat and gestation day 7-20 in the rabbit).
In rats, maternal toxicity was present at all doses and included six deaths and decreases in body weight gain and food consumption. Increased postimplantation losses were present in the mid dose group, which was 20 times the MRHD based on AUC. In rabbits, three spontaneous abortions and a single total litter loss were observed at the highest, maternally toxic dose, which was 12 times the MRHD based on AUC. A single total litter loss occurred at a lower non-maternally toxic dose of 150 mg/kg/day, which was 7 times the MRHD.
No fetal malformations were present at any dose level tested in either species even in the presence of maternal toxicity. At the highest doses tested, the exposure margins were 40 and 12 times the MRHD for the rat and rabbit, respectively. However, because elagolix binds poorly to the rat gonadotropin-releasing hormone (GnRH) receptor (~1000 fold less than to the human GnRH receptor), the rat study is unlikely to identify pharmacologically mediated effects of elagolix on embryofetal development. The rat study is still expected to provide information on potential non-target-related effects of elagolix.
In a pre- and postnatal development study in rats, elagolix was given in the diet to achieve doses of 0, 100 and 300 mg/kg/day (25 per dose group) from gestation day 6 to lactation day 20. There was no evidence of maternal toxicity. At the highest dose, two dams had total litter loss, and one failed to deliver. Pup survival was decreased from birth to postnatal day 4. Pups had lower birth weights and lower body weight gains were observed throughout the pre-weaning period at 300 mg/kg/day. Smaller body size and effect on startle response were associated with lower pup weights at 300 mg/kg/day. Post-weaning growth, development and behavioral endpoints were unaffected.
Maternal plasma concentrations in rats on lactation day 21 at 100 and 300 mg/kg/day (47 and 125 ng/mL) were 0.06-fold and 0.16-fold the maximal elagolix concentration (Cmax) in humans at the MRHD. Because the exposures achieved in rats were much lower than the human MRHD, this study is not predictive of potentially higher lactational exposure in humans.
There is no information on the presence of elagolix or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. There are no adequate animal data on the excretion of ORILISSA in milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ORILISSA and any potential adverse effects on the breastfed child from ORILISSA.
There are no adequate animal data on excretion of elagolix in milk.
Based on the mechanism of action, there is a risk of early pregnancy loss if ORILISSA is administered to a pregnant woman [see Pregnancy, CLINICAL PHARMACOLOGY].
ORILISSA may delay the ability to recognize the occurrence of a pregnancy because it may reduce the intensity, duration, and amount of menstrual bleeding. Exclude pregnancy before initiating treatment with ORILISSA. Perform pregnancy testing if pregnancy is suspected during treatment with ORILISSA and discontinue treatment if pregnancy is confirmed [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS].
Advise women to use effective non-hormonal contraception during treatment with ORILISSA and for 28 days after discontinuing ORILISSA [see WARNINGS AND PRECAUTIONS].
Safety and effectiveness of ORILISSA in pediatric patients have not been established.
No dose adjustment of ORILISSA is required in women with any degree of renal impairment or end-stage renal disease (including women on dialysis) [see CLINICAL PHARMACOLOGY].
No dosage adjustment of ORILISSA is required for women with mild hepatic impairment (Child-Pugh A). Only the 150 mg once daily regimen is recommended for women with moderate hepatic impairment (Child-Pugh B) and the duration of treatment should be limited to 6 months.
ORILISSA is contraindicated in women with severe hepatic impairment (Child-Pugh C) [see CONTRAINDICATIONS, and CLINICAL PHARMACOLOGY].
In case of overdose, monitor the patient for any signs or symptoms of adverse reactions and initiate appropriate symptomatic treatment, as needed.
ORILISSA is contraindicated in women:
ORILISSA is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of ORILISSA results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.
In a 3-menstrual cycle study in healthy women, ORILISSA 150 mg once daily and 200 mg twice daily resulted in an ovulation rate of approximately 50% and 32%, respectively. In the Phase 3 trials in women with endometriosis, ORILISSA caused a dose-dependent reduction in median estradiol concentrations to approximately 42 pg/mL for 150 mg once daily regimen and 12 pg/mL for the 200 mg twice daily regimen.
The effect of elagolix on the QTc interval was evaluated in a randomized, placebo-and positive-controlled, open-label, single-dose, crossover thorough QTc study in 48 healthy adult premenopausal women. Elagolix concentrations in subjects given a single dose of 1200 mg was 17-times higher than the concentration in subjects given elagolix 200 mg twice daily. There was no clinically relevant prolongation of the QTc interval.
The pharmacokinetic properties of ORILISSA in healthy subjects are summarized in Table 8. The steady state pharmacokinetic parameters under fasting conditions are summarized in Table 9.
Table 8. Pharmacokinetic Properties of ORILISSA in Healthy Subjects
| Absorption | |
| Tmax (h) | 1.0 |
| Effect of high-fat meal (relative to fasting) | AUC: ↓24%, Cmax: ↓36% |
| Distribution | |
| % Bound to human plasma proteins | 80 |
| Blood-to-plasma ratio | 0.6 |
| Metabolism | |
| Metabolism | CYP3A (major) Minor pathways include: CYP2D6, CYP2C8, and uridine glucuronosyl transferases (UGTs) |
| Elimination | |
| Major route of elimination | Hepatic metabolism |
| Terminal phase elimination half-life (t1/2) (h) | 4-6 |
| % of dose excreted in urine | <3 |
| % of dose excreted in feces | 90 |
Table 9. Mean (%CV) Steady State Pharmacokinetic Parameters of ORILISSA
| Pharmacokinetic Parameter (Units) |
150 mg Once Daily N = 6 |
200 mg Twice Daily N = 7 |
| Cmax (ng/mL) | 574 (29) | 774 (68) |
| AUCτ (ng•hr/mL) | 1292 (31) | 1725 (57) |
| CL/F (L/hr) | 123 (21) | 144 (43) |
| Vdss/F | 1674 (94) | 881 (38) |
| Rac | 0.98 (7) | 0.89 (19) |
| CV: Coefficient of variation Cmax: peak concentration AUCτ: area under the plasma concentration-time curve during the dosing interval (τ) i.e., 12 hours for twice daily regimen, 24 hours for once daily regimen. CL/F: oral clearance Vdss/F: apparent volume of distribution at steady state Rac: drug accumulation ratio |
||
Elagolix exposures (Cmax and AUC) are not altered by renal impairment. The mean exposures are similar for women with moderate to severe or end stage renal disease (including women on dialysis) compared to women with normal renal function.
Elagolix exposures (Cmax and AUC) are similar between women with normal hepatic function and women with mild hepatic impairment. Elagolix exposures in women with moderate and severe hepatic impairment are approximately 3-fold and 7-fold, respectively, higher than exposures from women with normal hepatic function [see Use In Specific Populations].
No clinically meaningful difference in the pharmacokinetics of ORILISSA between White and Black subjects or between Hispanics and others was observed. There is no clinically meaningful difference in the pharmacokinetics of ORILISSA between Japanese and Han Chinese subjects.
Body weight or body mass index does not affect the pharmacokinetics of ORILISSA.
Drug interaction studies were performed with ORILISSA and other drugs that are likely to be co-administered and with drugs commonly used as probes for pharmacokinetic interactions. Tables 10 and 11 summarize the pharmacokinetic effects when elagolix was co-administered with these drugs.
Table 10. Drug Interactions: Change in Pharmacokinetics of Elagolix in the Presence of Co-administered Drugs
| Co-administered Drug | Regimen of Co-administered Drug | Regimen of Elagolix | N | Ratio (90% CI)* | |
| Cmax | AUC | ||||
| Ketoconazole | 400 mg once daily | 150 mg single dose | 11 | 1.77 (1.48 – 2.12) |
2.20 (1.98 – 2.44) |
| Rifampin# | 600 mg single dose | 150 mg single dose | 12 | 4.37 (3.62 – 5.28) |
5.58 (4.88 – 6.37) |
| 600 mg once daily | 2.00 (1.66 – 2.41) |
1.65 (1.45 – 1.89) |
|||
| CI: Confidence interval *ratios for Cmax and AUC compare co-administration of the medication with elagolix vs. administration of elagolix alone. # A single dose of 600 mg rifampin inhibits OATP1B1; 600 mg once daily dose of rifampin inhibits OATP1B1 and induces CYP3A. |
|||||
No clinically significant changes in elagolix exposures were observed when co-administered with rosuvastatin (20 mg once daily), sertraline (25 mg once daily) or fluconazole (200 mg single dose).
Table 11. Drug Interactions: Change in Pharmacokinetics of Co-administered Drug in the Presence of Elagolix
| Co-administered Drug | Regimen of Co-administered Drug | Regimen of Elagolix | N | Ratio (90% CI)* | |
| Cmax | AUC | ||||
| Digoxin | 0.5 mg single dose | 200 mg twice daily x 10 days | 11 | 1.71 (1.53 – 1.91) |
1.26 (1.17 – 1.35) |
| Rosuvastatin | 20 mg once daily | 300 mg twice daily x 7 days | 10 | 0.99 (0.73 – 1.35) |
0.60 (0.50 – 0.71) |
| Midazolam | 2 mg single dose | 300 mg twice daily x 11 days | 20 | 0.56 (0.51 – 0.62) |
0.46 (0.41 – 0.50) |
| 150 mg once daily x 13 days | 11 | 0.81 (0.74 – 0.89) |
0.65 (0.58 – 0.72) |
||
| Norethindrone | 0.35 mg once daily x 112 days | 150 mg once daily x 56 days | 32 | 0.95 (0.86 – 1.05) |
0.88 (0.79 – 0.99) |
| Ethinyl Estradiol | Ethinyl estradiol 35 mcg and triphasic norgestimate 0.18/0.215/0.25 mg once daily | 150 mg once daily | 21 | 1.15 (1.07 – 1.25) |
1.30 (1.19 – 1.42) |
| Norelgestromina | 0.87 (0.78 – 0.97) |
0.85 (0.78 – 0.92) |
|||
| Norgestrela | 0.89 (0.78 – 1.00) |
0.92 (0.84 – 1.01) |
|||
| Ethinyl Estradiol | Ethinyl estradiol 20 mcg/Levonorgestrel 0.1 mg single dose | 200 mg twice daily x 15 days | 20 | 1.36 (1.27 – 1.45) |
2.18 (1.99 – 2.39) |
| Levonorgestrel | 0.97 (0.88 – 1.07) |
0.73 (0.64 – 0.82) |
|||
| Omeprazole | 40 mg single dose | 300 mg twice daily x 9 days | 20 | 1.95 (1.50 – 2.53) |
1.78 (1.39 – 2.27) |
| CI: Confidence interval *ratios for Cmax and AUC compare co-administration of the medication with elagolix vs. administration of the medication alone. a metabolite of norgestimate |
|||||
No clinically significant changes were observed in exposures of sertraline, fluconazole, or bupropion when co-administered with elagolix 300 mg twice daily.
Hepatic uptake of elagolix involves the OATP 1B1 transporter protein. Higher plasma concentrations of elagolix have been observed in patients who have two reduced function alleles of the gene that encodes OATP 1B1 (SLCO1B1 521T>C) (these patients are likely to have reduced hepatic uptake of elagolix and thus, higher plasma elagolix concentrations). The frequency of this SLCO1B1 521 C/C genotype is generally less than 5% in most racial/ethnic groups. Subjects with this genotype are expected to have a 78% mean increase in elagolix concentrations compared to subjects with normal transporter function (i.e., SLCO1B1 521T/T genotype). Adverse effects of elagolix have not been fully evaluated in subjects who have two reduced function alleles of the gene that encodes OATP1B1 (SLCO1B1 521T>C).
The efficacy of ORILISSA 150 mg once daily and 200 mg twice daily for the management of moderate to severe pain associated with endometriosis was demonstrated in two multinational double-blind, placebo-controlled trials in 1686 premenopausal women [Study EM-1 (NCT01620528) and Study EM-2 (NCT01931670)]. The median age of women in the trials was 32 years; 88% were White, 9% were Black or African American and 3% were other races. Each placebo-controlled trial assessed the reduction in endometriosis-associated pain over 6 months of treatment.
Moderate to severe pain associated with endometriosis was required for entry into the trials and was assessed during screening using the composite pelvic signs and symptoms score (CPSSS) and other baseline criteria.
The CPSSS is based on a modified Biberoglu and Behrman scale with five elements: three responses reported by study subjects (dysmenorrhea, dyspareunia, and non-menstrual pelvic pain) and two findings based on investigator assessment during physical examination (rating of pelvic tenderness and induration). Each element is scored from 0 (absent) to 3 (severe) for a maximum total score of 15. A total score of at least 6, with a score of at least 2 for dysmenorrhea and at least 2 for non-menstrual pelvic pain was required to qualify for randomization. Subjects were also required to have non-menstrual pelvic pain for at least four days in the preceding calendar month, defined as 35 days. Other criteria to determine eligibility for randomization included subject responses in a daily electronic diary (Endometriosis Daily Pain Impact Scale, described below) for both dysmenorrhea and non-menstrual pelvic pain in the 35 days prior to randomization.
The co-primary efficacy endpoints were (1) the proportion of subjects whose dysmenorrhea responded to treatment at Month 3 and (2) the proportion of subjects whose pelvic pain not related to menses (also known as non-menstrual pelvic pain) responded to treatment at Month 3. Dysmenorrhea and non-menstrual pelvic pain were evaluated daily using the Endometriosis Daily Pain Impact Scale that asked subjects to rate their pain severity and its impact on daily activities during the prior 24 hours as none, mild, moderate or severe (correlating with a score of 0 to 3, respectively, where higher scores indicated greater severity). Scores at baseline and at each month were averaged over a 35-day interval.
Women were defined as responders if they experienced a reduction in dysmenorrhea and non-menstrual pelvic pain as defined in Table 12 with no increase in analgesic use (nonsteroidal anti-inflammatory drug or opioid) for endometriosis-associated pain. The threshold for defining responders was based on a receiver operating characteristic (ROC) analysis using the patient global impression of change as an anchor. A higher proportion of women treated with ORILISSA 150 mg once daily or 200 mg twice daily were responders for dysmenorrhea and non-menstrual pelvic pain compared to placebo in a dose-dependent manner at Month 3 [see Table 12].
Table 12. Proportion of Responders† for Dysmenorrhea and Non-Menstrual Pelvic Pain at Month 3 in Studies EM-1 and EM-2, Using the Endometriosis Daily Pain Impact Scale
| Study EM-1 | Study EM-2 | |||||
| ORILISSA | Placebo | ORILISSA | Placebo | |||
| 150 mg Once Daily N=248 |
200 mg Twice Daily N=244 |
N=373 | 150 mg Once Daily N=221 |
200 mg Twice Daily N=225 |
N=353 | |
| Dysmenorrhea | 46% | 76% | 20% | 43% | 72% | 23% |
| Difference from placebo | 27%** | 56%** | 21%** | 50%** | ||
| Non-Menstrual Pelvic Pain | 50% | 55% | 36% | 50% | 58% | 37% |
| Difference from placebo | 14%** | 18%** | 13%* | 21%** | ||
| † Study EM-1-Dysmenorrhea responder threshold: at least 0.81 point decrease from baseline in dysmenorrhea score; Non-Menstrual Pelvic Pain responder threshold: at least 0.36 point decrease from baseline in Non-Menstrual Pelvic Pain score Study EM-2 -Dysmenorrhea responder threshold: at least 0.85 point decrease from baseline in dysmenorrhea score; Non-Menstrual Pelvic Pain responder threshold: at least 0.43 point decrease from baseline in Non-Menstrual Pelvic Pain score *p ≤0.01 for test of difference from placebo **p≤0.001 for test of difference from placebo |
||||||
Women in these studies also provided a daily self-assessment of their endometriosis pain using a numeric rating scale (NRS) that asked subjects to rate their endometriosis pain at its worst over the last 24 hours on a scale from 0 (no pain) to 10 (worst pain ever). In Study EM-1, baseline NRS scores were 5.7 for ORILISSA 150 mg once daily, 5.5 for ORILISSA 200 mg twice daily and 5.6 for placebo. In Study EM-2, baseline NRS scores were 5.7 for ORILISSA 150 mg once daily, 5.3 for ORILISSA 200 mg twice daily and 5.6 for placebo. Women taking ORILISSA 150 mg once daily and 200 mg twice daily reported a statistically (p <0.001) significant reduction from baseline in NRS scores compared to placebo at Month 3 in both Studies EM-1 and EM-2 (Study EM-1: 0.7 points for ORILISSA 150 mg once daily and 1.3 points for ORILISSA 200 mg twice daily; Study EM-2: 0.6 points for ORILISSA 150 mg once daily and 1.2 points for ORILISSA 200 mg twice daily).
In addition, both ORILISSA treatment groups showed statistically significantly greater mean decreases from baseline compared to placebo in dysmenorrhea and non-menstrual pelvic pain scores at Month 6. Figures 3 through 6 show the mean scores for dysmenorrhea and non-menstrual pelvic pain over time for Study EM-1 and EM-2.
Figure 3. Mean Dysmenorrhea Pain Scoresa in Study EM-1 Over 6 Months and Figure 4. Mean Dysmenorrhea Pain Scoresa in Study EM-2 Over 6 Months
 |
Figure 5. Mean Non-Menstrual Pelvic Paina Scores in Study EM-1 Over 6 Months and Figure 6. Mean Non-Menstrual Pelvic PainaScores in Study EM-2 Over 6 Months
 |
Dyspareunia associated with endometriosis was evaluated as a secondary endpoint using the Endometriosis Daily Pain Impact Scale that asked subjects to rate their pain during sexual intercourse in the prior 24 hours as none, mild, moderate, severe (correlating with a score of 0 to 3, respectively, where higher scores indicated greater severity), or not applicable. In both Studies EM-1 and EM-2, women treated with ORILISSA 200 mg twice daily showed statistically significantly greater reduction in dyspareunia from baseline to Month 3 than women given placebo (Study EM-1: 0.2; Study EM-2: 0.3). Figures 7 and 8 show the mean scores over time for Study EM-1 and EM-2.
Figure 7. Mean Dyspareunia Scoresa in Study EM-1 Over 3 Months and Figure 8. Mean Dyspareunia Scoresa in Study EM-2 Over 3 Months
 |
In EM-1 and EM-2, 59% and 60% of patients used an opioid rescue analgesic for pain at baseline. The opioid rescue analgesics used at baseline were predominantly hydrocodone/acetaminophen (HC/APAP) and codeine/APAP at strengths of 5/300-325 mg and 30/300-500 mg. In EM-1, of all patients on an opioid at baseline, 98% and 2% were on HC/APAP and codeine/APAP, respectively. In EM-2, of all patients on an opioid at baseline, 50% were on HC/APAP and 16% were on codeine/APAP.
Other data related to opioid rescue analgesic use are summarized in Table 13.
Table 13. Opioid Rescue Analgesic Use in EM-1 and EM-2
| Study EM-1 | Study EM-2 | |||||
| ORILISSA 150 mg Once Daily | ORILISSA 200 mg Twice Daily | Placebo | ORILISSA 150 mg Once Daily | ORILISSA 200 mg Twice Daily | Placebo | |
| Tablets per month at baseline (mean±SD) | 15 ±24 | 15 ±25 | 13 ±21 | 13 ±29 | 12 ±26 | 12 ±21 |
| Tablets per month at baseline [Median (Min, Max)] | 4 (0, 184) | 4 (0, 195) | 4 (0, 146) | 4 (0, 236) | 3 (0, 214) | 4 (0, 152) |
| Tablets per month at Month 3 (mean±SD) | 12 ±29 | 7 ±18 | 10 ±17 | 8 ±22 | 5 ±14 | 8 ±15 |
| Tablets per month at Month 3 [Median (Min, Max)] | 0 (0, 251) | 0 (0, 162) | 2 (0, 144) | 0 (0, 168) | 0 (0, 136) | 2 (0, 142) |
| Tablets per month at Month 6 (mean±SD) | 11 ±26 | 7 ±17 | 11 ±19 | 7 ±19 | 5 ±14 | 8 ±15 |
| Tablets per month at Month 6 [Median (Min, Max)] | 0 (0, 224) | 0 (0, 157) | 3 (0, 185) | 0 (0, 185) | 0 (0, 157) | 2 (0, 142) |
| Number and % of patients on any dose of opioid rescue at baseline who were off opioid at Month 3* | 46/150 (31%) | 59/151 (39%) | 36/211 (17%) | 44/124 (35%) | 68/134 (51%) | 54/220 (25%) |
| Number and % of patients on any dose of opioid rescue at baseline who were off opioid at Month 6* | 43/149 (29%) | 66/150 (44%) | 36/211 (17%) | 50/124 (40%) | 78/134 (58%) | 70/222 (32%) |
| Number and % of patients not on opioid rescue at baseline who were on any opioid at Month 3^ | 9/98 (9%) | 6/93 (6%) | 17/162 (10%) | 10/97 (10%) | 10/91 (11%) | 29/133 (22%) |
| Number and % of patients not on opioid rescue at baseline who were on any opioid at Month 6^ | 16/98 (16%) | 6/93 (6%) | 32/161 (20%) | 13/97 (13%) | 6/91 (7%) | 32/133 (24%) |
| Min = minimum; Max = maximum; SD = standard deviation Monthly calculations are based on a 35-day interval. *Denominator is the number of subjects on opioid rescue at baseline. ^Denominator is the number of subjects not on opioid rescue at baseline. |
||||||
The clinical relevance of these data has not been demonstrated.
ORILISSA®
(awr-ah-lih-sah)
(elagolix) tablets, for oral use
What is the most important information I should know about ORILISSA?
ORILISSA may cause serious side effects, including:
How What is ORILISSA?
ORILISSA is a prescription medicine used to treat moderate to severe pain associated with endometriosis. It is not known if ORILISSA is safe and effective in children.
Do not take ORILISSA if you:
Before you take ORILISSA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-thecounter medicines, vitamins, and herbal supplements.
Especially tell your healthcare provider if you take:
Know the medicines you take. Keep a list of your medicines with you to show to your healthcare provider and pharmacist when you get a new medicine.
How should I take ORILISSA?
What are the possible side effects of ORILISSA?
ORILISSA may cause serious side effects including:
You or your caregiver should pay attention to any changes, especially sudden changes in your mood, behaviors, thoughts, or feelings.
The most common side effects of ORILISSA include: hot flashes and night sweats, headache, nausea, difficulty sleeping, absence of periods, anxiety, joint pain, depression and mood changes. These are not all the possible side effects of ORILISSA. Call your healthcare provider for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.
How should I store ORILISSA?
General information about the safe and effective use of ORILISSA.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ORILISSA for a condition for which it was not prescribed. Do not give ORILISSA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ORILISSA that is written for health professionals.
What are the ingredients in ORILISSA?
Active ingredient: elagolix
Inactive ingredients 150 mg tablets: mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and carmine high tint.
Inactive ingredients 200 mg tablets: mannitol, sodium carbonate monohydrate, pregelatinized starch, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide red.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
